While many IBS patients are prescribed medication to help them control their symptoms, all of our customers have greatly benefited from Bowtrol. Our main ingredients are 100% natural, so Bowtrol will not interfere with any other drugs while it helps to manage your symptoms.

Research has shown positive effects of each of the Bowtrol ingredients on the symptoms of IBS, and combined they form a powerful product that can allow you to lead a more normal life

NEW YORK--Probiotic preparation containing Bowtrols Probiotic Lactospore relieved symptoms in patients suffering irritable bowel syndrome (IBS), according to a study published in the March issue of Gastroenterology. In the study (128, 3:541-51), Irish researchers gave 77 IBS patients either B. infantis 35624, Lactobacillus salivarius UCC4331 (Lactospore) or placebo for eight weeks, and assessed various IBS symptoms daily. B. infantis better alleviated all symptoms--including abdominal pain, bloating and bowel movement difficulty--than the other treatment. Researchers reported subjects' proinflammatory, Th-1 state was completely normalized by B. infantis feeding alone. They linked the effect to normalization of the ratio of an anti-inflammatory to a proinflammatory cytokine, suggesting an immune-modulating role for the probiotic strain in IBS patients. In addition, the scientists noted the symptom relief by B. infantis was comparable to effects shown by Zelnorm (tegaserod) and Lotronex (alosetron), two pharmaceuticals recently approved for IBS treatment.

Reports from various hospitals that performed clinical trials on groups of patients suffering from a variety of intestinal disorders and allergic skin diseases are summarized in Table 5.1.It is evident that the administration of L. sporogenes markedly improved the general clinical condition of the subjects and provided relief from intestinal disorders and allergic skin conditions. Allergic skin conditions can be related to an imbalance of intestinal flora66 in the subject . This condition was therefore corrected by L. sporogenes therapy in these trials.
SUMMARY OF SELECTED CLINICAL REPORTS FROM JAPAN : TRIALS WITH LACBONÒ (L. Sporogenes)

1. Condition: Acute and chronic intestinal catarrh

No. of subjects: 38
Treatment: 100-600 million spores/ day in divided doses for 2-12 days
Effectiveness rate: 86.8%
Conclusion: Recovery from diarrhea to regular normal stools; general symptoms including anorexia improved

2. Condition: Diarrhea

No. of subjects: 15
Treatment: 75-600 million spores/ day in divided doses for 3-12 days
Effectiveness rate: 100%
Conclusion: Recovery from diarrhea to regular, normal stools from third to fourth day

3. Condition: Constipation

No. of subjects: 10
Treatment: 300-750 million spores / day in divided doses for 2-10 days
Effectiveness rate: 70.0%
Conclusion: Recovery to normal stools and disappearance of abdominal distention

4. Condition: Abnormal intestinal fermentation

No. of subjects: 9
Treatment: 300-600 million spores / day in divided doses for 3-14 days
Effectiveness rate: 100.0%
Conclusion: Vomiting and nausea disappeared; appetite improved; stools became normal and regular; diarrhea and stomach ache cured.

5. Condition: Dyspepsia infantum

No. of subjects: 26
Treatment: 100-200 million spores / day in divided doses for 1-7 days
Effectiveness rate: 84.6%
Conclusion: General conditions and nature of stools improved. Frequency of stools decreased to half or less than that before medication.

6. Condition: Allergic skin diseases

No. of subjects: 5
Treatment: 200-450 million spores / day in divided doses for 4-12 days
Effectiveness rate: 80.0%
Conclusion: Obvious eruptions of strophulus and eczema decreased from the third day (topical therapy employed concomitantly)

7. Condition: Miscellaneous symptoms

No. of subjects: 10
Treatment: 20-50 million spores / day in divided doses for 4-20 days
Effectiveness rate: 80.0%
Conclusion: Response seen in anorexia of nervous type and malnutrition in infants

The above data are cited from clinical reports by: Terumichi Kuniya, Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta, Medical Clinic of Kugason Hospital; Goro Koide, Pediatric Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic of Ebara Hospital.

Studies with SPORLACÒ (L. sporogenes )59 in IndiaA total of 60 cases of neonatal diarrhea with watery stool frequency greater than 6 were examined for efficacy of SPORLAC treatment. Based on the suggested dosage level of SPORLAC at 5 million spores per kilogram body weight, each neonate was given a spore level of about 15 million spores per day. Some of the subjects had associated symptoms in addition to diarrhea